MedTrace Logo

Use of Tranexamic Acid in Reduction of Post-Op Complications in Mohs Micrographic Surgery

NCT04630886 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-11-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the use of locally injected tranexamic acid (TXA) under the skin during Mohs micrographic surgery for removal of skin cancers in patients on anticoagulation. TXA may be helpful in reducing bleeding and pain during surgery, and may also lead to fewer post-operative complications following surgery such as graft loss, specifically in patients on blood-thinners.

Conditions

  • Skin Neoplasms

Interventions

DRUG

Tranexamic acid injection

subcutaneous injection of 50mg/ml TXA

DRUG

Lidocaine Epinephrine

subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine

Sponsors & Collaborators

  • Riley McLean

    lead OTHER

Principal Investigators

  • Riley McLean, MD · University of Massachusetts, Worcester

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-16
Primary Completion
2024-01-16
Completion
2024-01-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04630886 on ClinicalTrials.gov